Contents

Search

risedronate (Actonel)

Indications: - Paget's disease of the bone - osteoporosis - prevention of bone loss in multiple myeloma - prevention of bone loss associated with corticosteroid therapy - prevention of bone loss associated with hypogonadism =- androgen deprivation therapy Dosage: 1) Paget's disease: 30 mg QD 2) osteoporosis: a) 5 mg PO QD; 35 mg PO weekly b) 75 mg PO on consecutive days monthly [8] c) 150 mg PO monthly d) duration of therapy unknown [9]* 3) do NOT take calcium at the same it as it may interfere with absorption 4) take with full glass of water 30 minutes before 1st meal 5) DO NOT LAY DOWN until after meal! * bone loss after discontinuation of therapy may be greater for risedronate than alendronate or zoledronate [9] Tabs: 5 mg, 35 mg for weekly dosing, 75 mg, 150 mg Adverse effects: 1) similar to alendronate [6] 2) erosive esophagitis Mechanism of action: 1) binds to bone hydroxyapatite 2) inhibits osteoclast activity 3) diminishes risk of hip fractures, vertebral fractures & other factures [10]

Interactions

drug interactions drug adverse effects of bisphosphonates

Related

Fosamax Actonel Comparison Trial

General

bisphosphonate

Properties

Database Correlations

PUBCHEM correlations

References

  1. The Prescriber's Letter, vol 6 #11, Nov 1999 - The Prescriber's Letter, vol 7 #5, May 2000
  2. Journal Watch, Mass Med Soc 19(23):183 (Dec) 1999
  3. Journal Watch, Mass Med Soc 19(24):190 (Dec) 1999
  4. Kaiser Permanente Northern California Regional Drug Formulary, Update 9/99
  5. Prescriber's Letter 7(8):47 2000 - Prescriber's Letter 9(6):31 2002
  6. Prescriber's Letter 10(8):47 2003
  7. Department of Veterans Affairs, VA National Formulary
  8. Prescriber's Letter 14(6): 2007 New Developments With Bisphosphonate Therapy Detail-Document#: 230613 (subscription needed) http://www.prescribersletter.com
  9. Whitaker M et al Bisphosphonates for Osteoporosis - Where Do We Go from Here? N Engl J Med 2012 May 9, PMID: 22571168 http://www.nejm.org/doi/full/10.1056/NEJMp1202619 - Black DM et al Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? N Engl J Med 2012 May 9, PMID: 22571169 http://www.nejm.org/doi/full/10.1056/NEJMp1202623
  10. Reid IR Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med. 2015 Jun;277(6):690-706 PMID: 25495429

Component-of

calcium carbonate/risedronate